Dr. Fernando Ignacio De Zarraga Jr., MD

Dr. De Zarraga practices at Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida.

Dr. De Zarraga's NPI, 1578550810, was assigned on October 3, 2005. Dr. De Zarraga graduated from University of Miami, Miller School of Medicine in 1998. Dr. De Zarraga holds Florida license ME0081464.

Dr. De Zarraga's primary practice is Baptist Health Baptist Hospital, at 8900 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (786) 596-1960.

Dr. De Zarraga's primary practice is Baptist Health Baptist Hospital in Miami, Florida, part of Baptist Health South Florida. Dr. De Zarraga is also affiliated with South Miami Hospital. The medical group on file is Baptist Health Medical Group Oncology. Dmand AI also links Dr. De Zarraga to 3 more hospitals and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. De Zarraga practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. De Zarraga's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. De Zarraga is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. De Zarraga treats.

CMS data shows 1,313 Medicare services from Dr. De Zarraga across 7 procedure codes in 2024, for 239 Medicare patients. Medicare paid $69,770 for them.

CMS counts 239 Medicare patients who saw Dr. De Zarraga in 2024. The largest group is 75 to 84, with 98 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. De Zarraga's median patient age at 67, with 47% women.

In 2024, Dr. De Zarraga wrote 495 Medicare Part D claims for 130 patients. 76% of them were for generic drugs. CMS names the drug for 334 of them, across 9 drugs with 11 or more claims each, at $71,342 in total drug cost. In 2023, CMS named 364 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. De Zarraga for performance year 2024, reported as part of a group. Dr. De Zarraga accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. De Zarraga as offering telehealth.

Dmand AI links 5 papers to Dr. De Zarraga, published from 2021 to 2024. The most frequent topics are Radiosurgery, Pancreatic Neoplasms and Radiotherapy Planning, Computer-Assisted. Dr. De Zarraga has published most often in Cancer Control. Dr. De Zarraga's most frequent co-authors are Santiago Aparo, MD, Michael David Chuong, MD and Antonio Ucar, MD.

Dmand AI links Dr. De Zarraga to 1 clinical trial. Conditions studied include Rectal Diseases and Colorectal Neoplasms.

CMS Open Payments shows 1,153 general payments to Dr. De Zarraga from 49 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 71% of the total. Millennium Pharmaceuticals, Inc. paid the most, $124,171.

Dr. De Zarraga graduated from University of Miami, Miller School of Medicine in 1998.

Dr. De Zarraga is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.